Nass Valley Gateway Ltd. Issues Shares Pursuant to the Acquisition of Advanced Bioceuticals Limited
All 280,000,000 issued common shares are subject to the four months hold period pursuant to the Canadian securities laws. 266,000,000 common shares are also subject to resale restrictions prescribed by the U.S. securities laws and cannot be resold during the next 12 months and without strict compliance with the U.S. securities laws. 261,400,000 common shares are also subject to an escrow agreement, a copy of which will be available under the profile of the Company on www.sedar.com.
After the completion of the acquisition, the Company is considered a "Non-foreign private issuer" under the definition of Rule 405 of the United States Securities Law Act of 1933 (the "Securities Act") and as a result will likely be classified as a "domestic issuer" pursuant to Rule 902(e) of Regulation S promulgated under the Securities Act and will have to comply with securities laws of the United States of America in addition to complying with the securities laws of applicable Canadian provinces.
The securities being offered have not been, nor will be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to U.S. persons without registration or applicable exemption from the registration requirement of such Act. This release does not constitute an offer for sale of such securities in the United States of America.
WE SEEK SAFE HARBOUR
Neither the CSE nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of the contents of this news release.
Trading Symbols: CSE: NVG
Deutsche Borse, Frankfurt: 3NVN, Germany: WKN A1JVHM/
Contact
Nass Valley Gateway Ltd.
Dieter Peter, President & CEO
Phone: 604-617-6794